IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): Substituted A substituted methylene amide derivative of Formula (I):

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

 R^1 is selected from the group consisting of (C_1-C_{15}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl or heterocycloalkyl, (C_1-C_{12}) alkyl-aryl or (C_1-C_{12}) alkyl-heteroaryl, (C_2-C_{12}) alkenyl-aryl or -heteroaryl, (C_2-C_{12}) alkynyl-aryl or -heteroaryl;

 R^{2a} and R^{2b} are each independently from each other selected from the group comprising or consisting of H or (C_1-C_{12}) alkyl;

Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group, with the proviso that the following compounds are excluded:

Claim 2 (Currently Amended): Substituted The substituted methylene amide derivatives derivative according to claim 1, wherein R^{2a} and R^{2b} are each H.

Claim 3 (Currently Amended): [[A]] <u>The</u> substituted methylene amide derivative according to claim 1 [[or 2]], wherein Cy is a thienyl or a phenyl group.

Claim 4 (Currently Amended): [[A]] <u>The</u> substituted methylene amide derivative according to claim 3, wherein Cy is a thienyl[[,]] <u>or a phenyl group</u> being substituted by a phenyl or an oxadiazole group or by 1 or 2 moieties selected from the group consisting of -NH-CO-R³, -SO₂-NR³R^{3'}, or -CO-NR³R^{3'} in which R³, R^{3'} are independently selected from H, (C₁-C₁₅)alkyl, (C₂-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, aryl, heteroaryl, (3-8-membered)cycloalkyl or heterocycloalkyl, (C₁-C₁₂)alkyl aryl or heteroaryl, (C₂-C₁₂)alkenyl-aryl or -heteroaryl, (C₂-C₁₂)alkynyl-aryl or -heteroaryl.

Claim 5 (Currently Amended): [[A]] The substituted methylene amide derivative according to claim 4, wherein R^{3} is H and R^{3} is selected from the group consisting of

diphenyl-ethyl, dodecyl, octyl, 4-pentyl-benzyl, 4-phenoxy-phenethyl, ethyl-thiophen-2-yl, pentadecyl, tridecyl, hexyloxy-phenyl or (2-ethyl)-hexyl.

Claim 6 (Currently Amended): [[A]] <u>The</u> substituted methylene amide <u>derivative</u> according to <u>any of claim 1 [[or 2]]</u>, wherein Cy is aryl, heteroaryl, (3-8-membered)-cycloalkyl or -heterocycloalkyl being substituted by a substituted or unsubstituted (C₂-C₁₈)alkynyl moiety.

Claim 7 (Currently Amended): [[A]] <u>The</u> substituted methylene amide <u>derivative</u> according to claim 6 wherein Cy is phenyl, pyridinyl, naphthyl or benzofuranyl group, being substituted by B-R⁴ wherein B is ethynyl group and R⁴ is (C₆-C₁₆)alkyl, (3-8 membered) cycloalkyl, (C₁-C₁₂)alkyl-(3-8 membered) cycloalkyl, phenyl or (C₁-C₁₂)alkyl phenyl.

Claim 8 (Currently Amended): [[A]] <u>The</u> substituted methylene amide <u>derivative</u> according to claim 7 wherein Cy is phenyl being substituted by $B-R^4$ wherein B is ethynyl group and R^4 is (C_6-C_{16}) alkyl.

Claim 9 (Currently Amended): [[A]] <u>The</u> substituted methylene amide derivative according to <u>any of claims 1 to 8 claim 1</u>, wherein R¹ is a moiety –CH₂-A, or -CH₂-CH₂-A with A being an aryl, heteroaryl, (3-8-membered)heterocycloalkyl or (3-8-membered)cycloalkyl.

Claim 10 (Currently Amended): [[A]] <u>The</u> substituted methylene amide derivative according to <u>any of claims 1 to 8 claim 1</u>, wherein R¹ is A, with A being aryl, heteroaryl, (3-8-membered)heterocycloalkyl or (3-8-membered)cycloalkyl.

Claim 11 (Currently Amended): [[A]] The substituted methylene amide derivative according to claim 9 or 10, wherein A is selected from the group consisting of phenyl, pyridinyl, benzo-1,3-dioxolenyl, biphenyl, naphthyl, quinoxalinyl, thiazolyl, thienyl, furanyl or a piperidinyl group, being optionally substituted by 1 or 2 cyano, halogen, NO₂, (C₁-C₆)alkoxy, aryloxy or heteroaryloxy, (C₁-C₆)thioalkoxy, (C₁-C₁₂)alkyl, (C₁-C₁₂)alkyl-X wherein X is halogen, (C₂-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, aryl, heteroaryl, (3-8 membered) cycloalkyl or heterocycloalkyl, (C₁-C₁₂)alkyl aryl or heteroaryl, (C₂-C₁₂)alkenyl aryl or heteroaryl, (C₂-C₁₂)alkynyl aryl or heteroaryl, -COR³, -COOR³, -CO-NR³R³, -NHCOR³ wherein R³ is a (C₁-C₁₂)alkyl or (C₁-C₁₂)alkenyl, -SOR³, -SO₂R³, -SO₂NR³R³, with R³, R³ being independently from each other selected from the group consisting of H, straight or branched (C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl or heterocycloalkyl.

Claim 12 (Currently Amended): [[A]] <u>The</u> substituted methylene amide derivative according to any claims 1 to 5 and 9 to 11 claim 1 wherein:

R^{2a} and R^{2b} are each H;

R¹ is–CH₂-A, with A being phenyl or thienyl, optionally substituted by cyano, halogen, methoxy, hydroxy, phenoxy, -NO₂, trifluoromethyl;

Cy is a thienyl, phenyl or biphenyl being substituted by $-SO_2R^3$, $-CO-NR^3R^3$ ' in which R^3 ' is H and R^3 is (C_7-C_{12}) alkyl, particularly (C_8-C_{12}) alkyl and more particularly a dodecyl group.

Claim 13 (Currently Amended): [[A]] <u>The</u> substituted methylene amide derivative according to [[any]] claim 1 to 5 and 9 to 11 wherein:

Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007

R^{2a} and R^{2b} are each H;

R¹ is-CH₂-A, with A being phenyl or thienyl, optionally substituted by cyano, halogen, methoxy, hydroxy, phenoxy, -NO₂, trifluoromethyl;

Cy is a thienyl, phenyl or biphenyl being substituted by $-SO_2R^3$, $-CO-NR^3R^3$ ' in which R^3 ' is H and R^3 is (C_7-C_{15}) alkyl, particularly (C_8-C_{15}) alkyl and more particularly a dodecyl group.

Claim 14 (Currently Amended): Substituted A substituted methylene amide derivative of Formula (I'): according to any of claims 1 to 5 or 9 to 11

wherein

 R^1 is selected from the group consisting of phenyl, benzyl, phenethyl, 1-methylbenzyl which may be substituted by (C_1-C_6) alkyl group or a cycloalkyl group;

Cy is a phenyl or a biphenyl group substituted with a moiety selected from the group consisting of -NH-CO-R³, -CO-NH-R³, or an oxadiazole group substituted with R³, wherein R^3 is (C_7-C_{15}) alkyl, particularly (C_8-C_{15}) alkyl and more particularly a dodecyl group.

Claim 15 (Currently Amended): A substituted methylene amide derivative according to any of the preceding claims selected from the following group consisting of:

(benzyl{4-[(dodecylamino)carbonyl] benzyl}amino)(oxo)acetic acid;

oxo{{4-[(pentadecylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzyl]amino}acetic acid;

(benzyl{4-[(pentadecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;

11

(oxo)acetic acid;

{({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)[4-(trifluoromethyl)benzyl]amino}-

{{4-[(dodecylamino)carbonyl]benzyl}{2-(4-phenoxyphenyl)ethyl]amino}(oxo)acetic

{{4-[(dodecylamino)carbonyl]benzyl}[2-(2-phenoxyphenyl)ethyl]amino}(oxo)acetic

acid;

acid;

 $\label{lem:carbonyl} $$\{benzyl[(3'-\{[(2,2-diphenylethyl)amino]carbonyl\}[1,1'-biphenyl]-4-yl)methyl]-amino}(oxo)acetic acid:$

benzyl]amino}acetic acid;

oxo{[4-({[2-(2-thienyl)ethyl]amino}carbonyl)benzyl][4-(trifluoromethyl)-

```
Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007
       \{(3-cyanobenzyl)[(3'-\{[(2,2-diphenylethyl)amino]carbonyl\}[1,1'-biphenyl]-4-
yl)methyllamino}(oxo)acetic acid;
       {(4-chlorobenzyl)[(3'-{[(2,2-diphenylethyl)amino]carbonyl}[1,1'-biphenyl]-4-
yl)methyl]amino}(oxo)acetic acid;
       {[(3'-{[(2,2-diphenylethyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)methyl][4-(trifluoro-
methyl)benzyl]amino}(oxo)acetic acid;
       ((3-cyanobenzyl)){[3'-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)[1,1'-biphenyl]-4-
yl]methyl}amino)(oxo)acetic acid;
       oxo{{[3'-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)[1,1'-biphenyl]-4-yl]methyl}-
[4-(trifluoromethyl)benzyl]amino}acetic acid;
       [(3-cyanobenzyl)({3'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl}methyl)amino]-
(oxo)acetic acid;
       [(4-chlorobenzyl)({3'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl}methyl)amino]-
(oxo)acetic acid;
       {({3'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl}methyl)[4-(trifluoromethyl)-
benzyl]amino}(oxo)acetic acid;
       {(3-cyanobenzyl)[(3'-{[(3-phenylpropyl)amino]carbonyl}[1,1'-biphenyl]-4-
yl)methyl]amino}(oxo)acetic acid;
       [(3-cyanobenzyl)({3'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl}methyl)-amino]-
(oxo)acetic acid;
       [(4-chlorobenzyl)({3'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl}methyl)-amino]-
(oxo)acetic acid;
       {({3'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl}methyl)[4-(trifluoromethyl)-
```

benzyl]amino}(oxo)acetic acid;

```
Reply to Restriction Requirement of November 16, 2007
       {benzyl[(3'-{[(4-pentylbenzyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)methyl]amino}-
(oxo)acetic acid;
       {(3-cyanobenzyl)[(3'-{[(4-pentylbenzyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)-
methyl]amino}(oxo)acetic acid;
       {(4-chlorobenzyl)[(3'-{[(4-pentylbenzyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)-
methyllamino}(oxo)acetic acid;
       oxo{[(3'-{[(4-pentylbenzyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)methyl][4-(trifluoro-
methyl)benzyl]amino}acetic acid;
       oxo{[(3'-{[(4-phenylbutyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)methyl][4-(trifluoro-
methyl)benzyl]amino}acetic acid;
       {(3-cyanobenzyl)[(3'-{[(2-mesitylethyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)-}
methyllamino}(oxo)acetic acid;
       {(4-chlorobenzyl)[(3'-{[(2-mesitylethyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)-
methyl]amino}(oxo)acetic acid;
       {[(3'-{[(2-mesitylethyl)amino]carbonyl}[1,1'-biphenyl]-4-yl)methyl][4-(trifluoro-
methyl)benzyl]amino}(oxo)acetic acid;
       ((4-\text{chlorobenzyl})\{[3'-(\{[2-(4-\text{methoxyphenyl})\text{ethyl}]\text{amino}\}\text{carbonyl})[1,1'-\text{biphenyl}]-
4-yllmethyl}amino)(oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(4-methoxybenzyl)amino](oxo)acetic acid;
       {{4-[(dodecylamino)carbonyl]benzyl}[4-(methylsulfonyl)benzyl]amino}(oxo)acetic
acid;
       [{3-[(dodecylamino)carbonyl]benzyl}(4-methoxybenzyl)amino](oxo)acetic acid;
       {{3-[(dodecylamino)carbonyl]benzyl}[3-(trifluoromethyl)benzyl]amino}(oxo)acetic
```

Application No. 10/501,344

acid;

```
({4-[(dodecylamino)carbonyl]benzyl} {[6-(trifluoromethyl)-3-pyridinyl]methyl}-amino)(oxo)acetic acid;
```

- 4-[((carboxycarbonyl){3-[(dodecylamino)carbonyl]benzyl}amino)methyl]benzoic acid;
- ({3-[(dodecylamino)carbonyl]benzyl} {4-[hydroxy(oxido)amino]benzyl}-amino)(oxo)acetic acid;
 - [{3-[(dodecylamino)carbonyl]benzyl}(2-fluorobenzyl)amino](oxo)acetic acid;
 [{3-[(dodecylamino)carbonyl]benzyl}(2-pyridinylmethyl)amino](oxo)acetic acid;
 [{3-[(dodecylamino)carbonyl]benzyl}(3-thienylmethyl)amino](oxo)acetic acid;
 [{3-[(dodecylamino)carbonyl]benzyl}(4-hydroxybenzyl)amino](oxo)acetic acid;
 [{3-[(dodecylamino)carbonyl]benzyl}(4-phenoxybenzyl)amino](oxo)acetic acid;
- ({3-[(dodecylamino)carbonyl]benzyl} {[6-(trifluoromethyl)-3-pyridinyl]methyl}-amino)(oxo)acetic acid;
- 3-[((carboxycarbonyl){3-[(dodecylamino)carbonyl]benzyl}amino)methyl]benzoic acid;
- 5-[((carboxycarbonyl){3-[(dodecylamino)carbonyl]benzyl}amino)methyl]-2-thiophenecarboxylic acid;
- ({4-[(dodecylamino)carbonyl]benzyl} {4-[hydroxy(oxido)amino]-benzyl}-amino)(oxo)acetic acid;
- ((1,3-benzodioxol-5-ylmethyl){4-[(dodecylamino)carbonyl]-benzyl}amino)-(oxo)-acetic acid;
 - [{4-[(dodecylamino)carbonyl]benzyl}(2-fluorobenzyl)amino](oxo)acetic acid; [{4-[(dodecylamino)carbonyl]benzyl}(4-phenoxybenzyl)amino](oxo)acetic acid; 4-[((carboxycarbonyl){4-[(dodecylamino)carbonyl]benzyl}amino)methyl]benzoic

acid;

5-[((carboxycarbonyl) {4-[(dodecylamino)carbonyl]benzyl} amino)methyl]-2-thiophenecarboxylic acid;

[{3-[(dodecylamino)carbonyl]benzyl}(2-thienylmethyl)amino](oxo)acetic acid;
[{4-[(dodecylamino)carbonyl]benzyl}(isopropyl)amino](oxo)acetic acid;
((3,5-dichlorobenzyl){4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
[(3,5-dichlorobenzyl)(4-{[(3,3-diphenylpropyl)amino]carbonyl}-benzyl)amino](oxo)acetic acid;

[(4-{[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl}benzyl)(3,5-dichlorobenzyl)-amino](oxo)acetic acid;

[(1,3-benzodioxol-5-ylmethyl)(4-{[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl}-benzyl)amino](oxo)acetic acid;

(2,3-dihydro-1H-inden-1-yl{4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;

{2,3-dihydro-1H-inden-1-yl[4-({[2-(4-phenoxyphenyl)ethyl]amino}-carbonyl)-benzyl]amino}(oxo)acetic acid;

[{4-[(dodecylamino)carbonyl]benzyl}(4-pyridinylmethyl)amino](oxo)acetic acid; ([4-(dimethylamino)benzyl]{4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;

[{4-[(dodecylamino)carbonyl]benzyl}(3-pyridinylmethyl)amino](oxo)acetic acid;
((4-cyanobenzyl){4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
[{4-[(dodecylamino)carbonyl]benzyl}(1,3-thiazol-2-ylmethyl)amino](oxo)acetic acid;
({4-[(dodecylamino)carbonyl]benzyl}{[2-(4-morpholinyl)-1,3-thiazol-5-yl]methyl}amino)(oxo)acetic acid;

[{3-[(dodecylamino)carbonyl]benzyl}(4-pyridinylmethyl)amino](oxo)acetic acid; [{3-[(dodecylamino)carbonyl]benzyl}(3-pyridinylmethyl)amino](oxo)acetic acid;

```
[{3-[(dodecylamino)carbonyl]benzyl}(3-hydroxybenzyl)amino](oxo)acetic acid;
       ((4-cyanobenzyl){3-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
       [{3-[(dodecylamino)carbonyl]benzyl}(1,3-thiazol-2-ylmethyl)amino](oxo)acetic acid;
       ({3-[(dodecylamino)carbonyl]benzyl}{[2-(4-morpholinyl)-1,3-thiazol-5-yl]methyl}-
amino)(oxo)acetic acid;
       ((1,3-benzodioxol-5-ylmethyl){3-[(dodecylamino)carbonyl]-benzyl}amino)-
(oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(2-thienylmethyl)amino](oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(2-pyridinylmethyl)amino](oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(3-thienylmethyl)amino](oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(4-hydroxybenzyl)amino](oxo)acetic acid;
       3-[((carboxycarbonyl){4-[(dodecylamino)carbonyl]benzyl}amino)methyl]benzoic
acid;
       [cyclopentyl({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino](oxo)acetic acid;
       [benzyl({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino](oxo)acetic acid;
       (({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl){3-[hydroxy(oxido)amino]-benzyl}-
amino)(oxo)acetic acid;
       [({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(4-methoxybenzyl)amino]-(oxo)-
acetic acid;
       [({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(2-fluorobenzyl)amino](oxo)acetic
acid;
       {({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)[4-(methylsulfonyl)-benzyl]-
amino}(oxo)acetic acid;
       [({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(4-phenoxybenzyl)amino]-(oxo)-
acetic acid;
```

- 4-{[(carboxycarbonyl)({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)-amino]-methyl}benzoic acid;
- (({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl){[6-(trifluoromethyl)-3-pyridinyl]-methyl}amino)(oxo)acetic acid;
- {({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)[3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
- [(3-chlorobenzyl)({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino](oxo)acetic acid;
- {[(5-{[(3,3-diphenylpropyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)-benzyl]amino}(oxo)acetic acid;
- {(3-chlorobenzyl)[(5-{[(3,3-diphenylpropyl)amino]sulfonyl}-2-thienyl)methyl]-amino}(oxo)acetic acid;
- oxo{{[5-({[2-(4-phenoxyphenyl)ethyl]amino}sulfonyl)-2-thienyl]methyl}[3-(trifluoromethyl)benzyl]amino}acetic acid;
- ((3-chlorobenzyl){[5-({[2-(4-phenoxyphenyl)ethyl]amino}sulfonyl)-2-thienyl]-methyl}amino)(oxo)acetic acid;
- {[(5-{[(2-[1,1'-biphenyl]-4-ylethyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
- (({1-[(cyclohexylamino)carbonyl]-4-piperidinyl}methyl){4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
- ([(1-{[4-(dimethylamino)anilino]carbonyl}-4-piperidinyl)methyl]{4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
- {{4-[(dodecylamino)carbonyl]benzyl}[(1-hexanoyl-4-piperidinyl)methyl]-amino}(oxo)acetic acid;

```
Reply to Restriction Requirement of November 16, 2007
                ({4-[(dodecylamino)carbonyl]benzyl}{[1-(3-iodobenzoyl)-4-piperidinyl]methyl}-
amino)(oxo)acetic acid;
                 {{4-[(dodecylamino)carbonyl]benzyl}[(1-{(2E)-3-[3-(trifluoromethyl)phenyl]-2-
propenoyl\-4-piperidinyl\methyl\amino\(oxo\)acetic acid;
                ({4-[(dodecylamino)carbonyl]benzyl} {[1-(2-quinoxalinylcarbonyl)-4-piperidinyl]-
methyl}amino)(oxo)acetic acid;
                [({1-[(4-methoxyphenyl)sulfonyl]-4-piperidinyl}methyl)(4-{[(4-
phenoxybenzyl)amino|carbonyl}benzyl)amino|(oxo)acetic acid;
                [{[1-(3-iodobenzoyl)-4-piperidinyl]methyl}(4-{[(4-phenoxybenzyl)amino]-
carbonyl}benzyl)amino](oxo)acetic acid;
                oxo\{(4-\{[(4-phenoxybenzyl)amino]carbonyl\}benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]\}benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl)[(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl]benzyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])amino]carbonyl][(1-\{(2E)-3-[3-k])a
(trifluoromethyl)phenyl]-2-propenoyl}-4-piperidinyl)methyl]amino}acetic acid;
                 {{4-[(dodecylamino)carbonyl]phenyl}[2-(methoxycarbonyl)benzyl]-
amino}(oxo)acetic acid;
                [[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl](4-iodobenzyl)-
amino](oxo)acetic acid;
                 [(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(4-iodobenzyl)amino]-
(oxo)acetic acid;
                [{2-bromo-4-[(dodecylamino)carbonyl]benzyl}(4-iodobenzyl)amino](oxo)acetic acid;
                [(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(4-iodobenzyl)amino]-
(oxo)acetic acid;
                yl]methyl}amino)(oxo)acetic acid;
                 {[2-bromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl][(4'-fluoro-1,1'-
biphenyl-3-yl)methyl]amino}(oxo)acetic acid;
```

Application No. 10/501,344

{[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid;

{(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid;

{[2,6-dibromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid:

{[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2,6-dibromobenzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid;

{(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid;

{{2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl}[(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid;

([(4'-fluoro-1,1'-biphenyl-3-yl)methyl] {[4'-({[2-(4-phenoxyphenyl)ethyl]amino}-carbonyl)-1,1'-biphenyl-4-yl]methyl} amino)(oxo)acetic acid;

{({4'-[(dodecylamino)carbonyl]-1,1'-biphenyl-4-yl}methyl)[(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino}(oxo)acetic acid;

{(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[2-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;

{(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[2-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;

oxo{{[4'-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)-1,1'-biphenyl-4-yl]methyl}[2-(trifluoromethoxy)benzyl]amino}acetic acid;

{({4'-[(dodecylamino)carbonyl]-1,1'-biphenyl-4-yl}methyl)[2-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;

```
Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007
       [[2-bromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl](3-phenoxy-
benzyl)amino](oxo)acetic acid;
       [[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl](3-
phenoxybenzyl)amino](oxo)acetic acid;
       [(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(3-phenoxybenzyl)-
amino](oxo)acetic acid;
       [[2,6-dibromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl](3-
phenoxybenzyl)amino](oxo)acetic acid;
       [[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2,6-dibromobenzyl](3-phenoxy-
benzyl)amino](oxo)acetic acid;
       [(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(3-phenoxybenzyl)-
aminol(oxo)acetic acid;
       [{2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl}(3-phenoxybenzyl)amino](oxo)-
acetic acid;
       oxo((3-phenoxybenzyl){[4'-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)-1,1'-
biphenyl-4-yl]methyl}amino)acetic acid;
       oxo[[(4'-{[(4-pentylbenzyl)amino]carbonyl}-1,1'-biphenyl-4-yl)methyl](3-
phenoxybenzyl)aminolacetic acid;
       [({4'-[(dodecylamino)carbonyl]-1,1'-biphenyl-4-yl}methyl)(3-phenoxybenzyl)-
amino](oxo)acetic acid;
       [[2-bromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl](2-iodobenzyl)-
```

[[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl](2-iodobenzyl)-

aminol(oxo)acetic acid;

amino](oxo)acetic acid;

[(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(2-iodobenzyl)amino](oxo)acetic acid;

[{2-bromo-4-[(dodecylamino)carbonyl]benzyl}(2-iodobenzyl)amino](oxo)acetic acid; ([2-bromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl]{[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

([4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl]{[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

((2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl){[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

((2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl){[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

({2-bromo-4-[(dodecylamino)carbonyl]benzyl} {[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

 $([4-(\{[2-(1,1'-biphenyl-4-yl)ethyl]amino\}carbonyl)-2,6-dibromobenzyl]\{[2'-(tri-fluoromethyl)-1,1'-biphenyl-4-yl]methyl\}amino)(oxo)acetic acid;$

((2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl){[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

({2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl} {[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

(({4'-[(dodecylamino)carbonyl]-1,1'-biphenyl-4-yl}methyl){[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}amino)(oxo)acetic acid;

[[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl](1,1'-biphenyl-2-ylmethyl)amino](oxo)acetic acid;

[(1,1'-biphenyl-2-ylmethyl)(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)-amino](oxo)acetic acid;

- ((1,1'-biphenyl-2-ylmethyl){2-bromo-4-[(dodecylamino)carbonyl]benzyl}-amino)(oxo)acetic acid;
- {(1,1'-biphenyl-2-ylmethyl)[2,6-dibromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}-carbonyl)benzyl]amino}(oxo)acetic acid;
- [[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2,6-dibromobenzyl](1,1'-biphenyl-2-ylmethyl)amino](oxo)acetic acid;
- [(1,1'-biphenyl-2-ylmethyl)(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}-benzyl)amino](oxo)acetic acid;
- ((1,1'-biphenyl-2-ylmethyl) {2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl}-amino)(oxo)acetic acid;
- {(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;
- {{2-bromo-4-[(dodecylamino)carbonyl]benzyl}[4-(trifluoromethoxy)benzyl]amino}(oxo)acetic acid;
- $\label{lem:condition} $$ \{(2,6-dibromo-4-\{[(4-pentylbenzyl)amino]carbonyl\}benzyl)[4-(trifluoromethoxy)-benzyl]amino\}(oxo)acetic acid: $$ (2,6-dibromo-4-\{[(4-pentylbenzyl)amino]carbonyl]benzyl]amino} $$ (0xo)acetic acid: $$ (2,6-dibromo-4-\{[(4-pentylbenzyl)amino]carbonyl]benzyl]amino} $$ (0xo)acetic acid: $$ (2,6-dibromo-4-\{[(4-pentylbenzyl)amino]carbonyl]benzyl]amino} $$ (2,6-dibromo-4-(2-pentylbenzyl)amino} $$ (2$
- {(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[3-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;
- {{2-bromo-4-[(dodecylamino)carbonyl]benzyl}[3-(trifluoromethoxy)benzyl]amino}(oxo)acetic acid;
- {(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[3-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;
- {{2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl}[3-(trifluoromethoxy)benzyl]-amino}(oxo)acetic acid;

{({4'-[(dodecylamino)carbonyl]-1,1'-biphenyl-4-yl}methyl)[3-(trifluoromethoxy)-benzyl]amino}(oxo)acetic acid;

[[2-bromo-4-({[2-(4-phenoxyphenyl)ethyl]amino}carbonyl)benzyl](4-phenoxybenzyl)amino](oxo)acetic acid;

[[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl](4-phenoxy-benzyl)amino](oxo)acetic acid;

[(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(4-phenoxybenzyl)-amino](oxo)acetic acid;

[{2-bromo-4-[(dodecylamino)carbonyl]benzyl}(4-phenoxybenzyl)amino](oxo)acetic acid;

[[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2,6-dibromobenzyl](4-phenoxy-benzyl)amino](oxo)acetic acid;

[(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(4-phenoxybenzyl)-amino](oxo)acetic acid;

{[4-({[2-(1,1'-biphenyl-4-yl)ethyl]amino}carbonyl)-2-bromobenzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(2-bromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzyl]-amino}(oxo)acetic acid;

{{2-bromo-4-[(dodecylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(2,6-dibromo-4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzyl]amino}(oxo)acetic acid;

{{2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

```
oxo{[(4'-{[(4-pentylbenzyl)amino]carbonyl}-1,1'-biphenyl-4-yl)methyl][4-(trifluoro-
methyl)benzyl]amino}acetic acid;
       {{2-bromo-4-[(dodecylamino)carbonyl]benzyl}[3-(trifluoromethyl)benzyl]-
amino}(oxo)acetic acid;
       {{2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl}[3-(trifluoromethyl)benzyl]-
amino}(oxo)acetic acid;
       oxo{[(4'-{[(4-pentylbenzyl)amino]carbonyl}-1,1'-biphenyl-4-yl)methyl][3-
(trifluoromethyl)benzyl]amino}acetic acid;
       {(4-dibenzo[b,d]furan-4-ylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {(4-dibenzo[b,d]furan-4-ylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid,
N-methyl-D-glucamine (i.e. 1 deoxy-1 (methylamino)glucitol) salt;
       ({4-[(dodecylamino)carbonyl]benzyl}{1-[4-(trifluoromethyl)phenyl]ethyl}amino)-
(oxo)acetic acid;
       ({4-[(dodecylamino)carbonyl]benzyl}{1-[4-(trifluoromethyl)phenyl]ethyl}amino)-
(oxo)acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1 (methylamino)glucitol) salt;
       {({4'-[(octylamino)carbonyl]-1,1'-biphenyl-4-yl}methyl)[4-(trifluoromethyl)benzyl]-
amino}(oxo)acetic acid;
       oxo{(4-tetradec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino} acetic acid;
       {(4-dodec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {{4-[(dodecylamino)carbonyl]benzyl}[4-(trifluoromethyl)phenyl]amino}(oxo)acetic
acid;
      [{4-[(dodecylamino)carbonyl]benzyl}(2-methoxyphenyl)amino](oxo)acetic acid;
       ((1,2-diphenylethyl){4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
      N-(carboxycarbonyl)-N-{4-[(dodecylamino)carbonyl]benzyl}-L-phenylalanine;
      [44-[(dodecylamino)carbonyl]benzyl}(3-phenoxyphenyl)amino](oxo)acetic acid;
```

```
[{4-[(dodecylamino)carbonyl]benzyl}(2-isopropoxyphenyl)amino](oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(4-iodophenyl)amino](oxo)acetic acid;
       {{4-[(dodecylamino)carbonyl]benzyl}[3-fluoro-4-(trifluoromethyl)benzyl]-
amino}(oxo)acetic acid;
       ((3-chloro-2-methylphenyl) {4-[(dodecylamino)carbonyl]benzyl} amino)(oxo)acetic
acid;
       4'-((carboxycarbonyl){4-[(dodecylamino)carbonyl]benzyl}amino)-1,1'-biphenyl-2-
carboxylic acid;
       ((2,4-dichlorobenzyl) {4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(1-phenylpropyl)amino](oxo)acetic acid;
       ([2-(4-chlorophenyl)propyl] {4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic
acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(4-isopropoxyphenyl)amino](oxo)acetic acid;
       ([4-(benzyloxy)phenyl]{4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
       {{4-[(dodecylamino)carbonyl]benzyl}[2-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       [{4-[(dodecylamino)carbonyl]benzyl}(2-methoxybenzyl)amino](oxo)acetic acid;
       ([(1R)-1-(4-chlorophenyl)ethyl]{4-[(dodecylamino)carbonyl]benzyl}amino)-
(oxo)acetic acid;
       ((3,4-dichlorobenzyl) {4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;
       ((1-benzothien-3-ylmethyl){4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic
acid;
       ([2-(2,6-dichlorophenyl)ethyl] {4-[(dodecylamino)carbonyl]benzyl}amino)(oxo)acetic
acid;
```

{(1-{4-[(dodecylamino)carbonyl]phenyl}ethyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(1-{4-[(dodecylamino)carbonyl]phenyl}ethyl)[4-(trifluoromethyl)benzyl]amino}-(oxo)acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;

([2-(3-chlorophenyl)ethyl]{4-[(1Z)-dec-1-enyl]benzyl}amino)(oxo)acetic acid;

[[2-(3-chlorophenyl)ethyl](4-dec-1-ynylbenzyl)amino](oxo)acetic acid;

```
Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007
```

{[2-(3-chlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)-acetic acid;

{[2-(3-chlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)-acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;

 $oxo \{\{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl\}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino\} acetic acid;$

oxo{{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)-glucitol) salt;

oxo{[4-(trifluoromethyl)phenyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-acetic acid;

oxo{[4-(trifluoromethyl)phenyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1 (methylamino)glucitol) salt;

oxo{{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}acetic acid;

oxo{{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)-glucitol) salt;

[(3-chlorobenzyl)(4-dec-1-ynylbenzyl)amino](oxo)acetic acid;

[(3-chlorobenzyl)(4-dec-1-ynylbenzyl)amino](oxo)acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;

[[2-(3-chlorophenyl)ethyl](4-oct-1-ynylbenzyl)amino](oxo)acetic acid;

[[2-(3-chlorophenyl)ethyl](4-oct-1-ynylbenzyl)amino](oxo)acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1 (methylamino)glucitol) salt;

{(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino}(oxo)acetic acid;

acetic acid;

((4-dec-1-ynylbenzyl){1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl}amino)(oxo)-

```
((4-dec-1-ynylbenzyl){1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl}amino)(oxo)-
acetic acid, N-methyl-D-glucamine (i.e. 1 deoxy-1 (methylamino)glucitol) salt;
       oxo{{4-[(9Z)-tetradec-9-enoylamino]benzyl}[4-(trifluoromethyl)benzyl]amino}-
acetic acid;
       {(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       oxo {[4-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]-
amino}acetic acid;
       oxo{[4-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;
       {(4-dodecylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {(4-dodecylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid, N-methyl-D-
glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;
       {[4-({[(2-butyl-1-benzofuran-3-yl)methyl]amino}carbonyl)benzyl][4-(trifluoro-
methyl)benzyllamino}(oxo)acetic acid;
       {(4-{[4-(benzyloxy)benzoyl]amino}benzyl)[4-(trifluoromethyl)benzyl]amino}-
(oxo)acetic acid;
       {(3,5-dichlorobenzyl)[4-(tridecanoylamino)benzyl]amino}(oxo)acetic acid;
       {(3.5-dichlorobenzyl)[4-(tridecanoylamino)benzyl]amino}(oxo)acetic acid, N-methyl-
D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;
       {{4-[(4-octylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       oxo{[4-(trifluoromethyl)benzyl][4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino}-
acetic acid;
       oxo{[4-(trifluoromethyl)benzyl][4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino}-
acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;
```

{[4-(11-methoxy-11-oxoundec-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

11-[4-({(carboxycarbonyl)[4-(trifluoromethyl)benzyl]amino}methyl)phenyl]undec-10-ynoic acid;

```
Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007
       {(4-{[4-(benzyloxy)phenyl]ethynyl}benzyl)[4-(trifluoromethyl)benzyl]amino}-
(oxo)acetic acid;
       {(4-{2-[4-(heptyloxy)phenyl]ethyl}benzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)-
acetic acid;
       {{4-[2-(4-butylphenyl)ethyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {{4-[2-(4-hexylphenyl)ethyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {{4-[2-(4-hexylphenyl)ethyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;
       oxo{(4-{2-[4-(pentyloxy)phenyl]ethyl}benzyl)[4-(trifluoromethyl)benzyl]-
amino}acetic acid;
       oxo{{4-[2-(4-propylphenyl)ethyl]benzyl}[4-(trifluoromethyl)benzyl]amino}acetic
acid;
       11-[4-({(carboxycarbonyl)[4-(trifluoromethyl)benzyl]amino}methyl)phenyl]-
undecanoic acid;
       {[4-(11-hydroxyundecyl)benzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {(4-dodec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino}(oxo)acetic acid;
       {(4-dodec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino}(oxo)acetic acid, N-
methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;
```

oxo([4-(trifluoromethyl)benzyl]{4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl}-amino)acetic acid, N-methyl-D-glucamine (i.e. 1-deoxy-1-(methylamino)glucitol) salt;

amino)acetic acid;

oxo([4-(trifluoromethyl)benzyl]{4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl}-

{(3-dodec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

```
Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007
       {[2-(2-fluorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       {[2-(2-fluorophenyl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       {[2-(2-fluorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic
acid;
       {[2-(3,4-dichlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       {[2-(3,4-dichlorophenyl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       {[2-(3,4-dichlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-
vl)benzyllamino}(oxo)acetic acid;
       \{[2-(1,1'-biphenyl-4-yl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino\}-
(oxo)acetic acid;
       {[2-(1,1'-biphenyl-4-yl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       \{[2-(1,1'-biphenyl-4-yl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       oxo{5,6,7,8-tetrahydronaphthalen-1-yl[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]-
amino}acetic acid;
       oxo\{5,6,7,8-tetrahydronaphthalen-1-yl[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]-
amino}acetic acid;
       [[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl](5,6,7,8-tetrahydronaphthalen-1-yl)amino]-
```

(oxo)acetic acid;

```
Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007
       {(1,1'-biphenyl-3-ylmethyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       {(1,1'-biphenyl-3-ylmethyl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
(oxo)acetic acid;
       \{(1,1'-biphenyl-3-ylmethyl)[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino\}-(oxo)-
acetic acid;
       {(1-benzothien-3-vlmethyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-(oxo)-
acetic acid;
       {(1-benzothien-3-ylmethyl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)-
acetic acid;
       {(1-benzothien-3-ylmethyl)[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)-
acetic acid;
       oxo{[2-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-
acetic acid;
       oxo{[2-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-
yl)benzyl]amino}acetic acid;
       {[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl][2-(trifluoromethyl)benzyl]amino}(oxo)-
acetic acid;
       oxo{[3-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]-amino}-
acetic acid;
       oxo{[3-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]-amino}-
```

{[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl][3-(trifluoromethyl)benzyl]amino}-(oxo)-

acetic acid;

acetic acid;

```
{(2-methoxybenzyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic
acid {(2-methoxybenzyl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)-acetic acid;
       {(2-methoxybenzyl)[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic acid;
       oxo{{4-[(trifluoromethyl)sulfonyl]benzyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-
benzyllamino} acetic acid;
       oxo{{4-[(trifluoromethyl)sulfonyl]benzyl}[3-(3-undecyl-1,2,4-oxadiazol-5-yl)-
benzyl]amino}acetic acid;
       ([4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]{4-[(trifluoromethyl)-sulfonyl]benzyl}-
amino)(oxo)acetic acid;
       {1,3-benzodioxol-5-yl[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic
acid;
       {1,3-benzodioxol-5-yl[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic
acid;
       {1,3-benzodioxol-5-yl[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic
acid;
       {[(4-dodec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {[(4-dec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {[(4-dec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       oxo{[4-(trifluoromethyl)benzyl][4-(4-undecyl-1,3-thiazol-2-yl)benzyl]amino}acetic
acid;
       {(4-dec-1-ynylbenzyl)[2-(2-fluorophenyl)ethyl]amino}(oxo)acetic acid;
       {(4-dodec-1-vnylbenzyl)[2-(2-fluorophenyl)ethyl]amino}(oxo)acetic acid;
```

```
{{[4-(dodecyloxy)-1-naphthyl]methyl}[2-(2-fluorophenyl)ethyl]amino}(oxo)acetic
acid;
       {[2-(2-fluorophenyl)ethyl][4-(octyloxy)benzyl]amino}(oxo)acetic acid;
       {(4-dec-1-ynylbenzyl)[2-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {(4-dodec-1-ynylbenzyl)[2-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {{[4-(dodecyloxy)-1-naphthyl]methyl}[2-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {[4-(octyloxy)benzyl][2-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {(4-dec-1-ynylbenzyl)[2-(3,4-dichlorophenyl)ethyl]amino}(oxo)acetic acid;
       [[2-(3,4-dichlorophenyl)ethyl](4-dodec-1-ynylbenzyl)amino](oxo)acetic acid;
       ([2-(3,4-dichlorophenyl)ethyl]{[4-(dodecyloxy)-1-
naphthyl]methyl}amino)(oxo)acetic acid;
       {[2-(3,4-dichlorophenyl)ethyl][4-(octyloxy)benzyl]amino}(oxo)acetic acid;
       ({4-[(4-hexylphenyl)ethynyl]benzyl}{1-methyl-1-[4-
(trifluoromethyl)phenyl]ethyl}amino)(oxo)acetic acid;
       {[4-(5-cyclohexylpent-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {{3-[(4-hexylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic
acid;
       {[4-(4-ethyl-3-hydroxyoct-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino}-(oxo)-
acetic acid;
       {(2-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;
       {(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid, L-lysine
salt;
```

Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007

{(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid, tromethamine (i.e. (2-amino-2-hydroxymethyl)-1,3-propanediol) salt;

{(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid, L-Arginine salt;

Sodium {(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetate.

Claim 16 (Currently Amended): Substituted A substituted methylene amide derivative of Formula (I):

$$\begin{array}{c|cccc}
R^{2a} & R^{1} \\
Cy & N & O \\
R^{2b} & O & OH
\end{array}$$
O OH

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

 R^1 is selected from the group consisting of (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, aryl, heteroaryl, (3-8-membered)cycloalkyl or heterocycloalkyl, (C_1-C_{12}) alkyl-aryl or (C_1-C_{12}) alkyl-heteroaryl, (C_2-C_{12}) alkenyl-aryl or -heteroaryl, (C_2-C_{12}) alkynyl-aryl or -heteroaryl;

 R^{2a} and R^{2b} are each independently from each other selected from the group comprising or consisting of H or (C_1-C_{12}) alkyl;

Cy is an aryl, heteroaryl, cycloalkyl or heterocycle, for use as a medicament, with the proviso that the following compounds are excluded:

Claim 17 (Currently Amended): Substituted The substituted methylene amide derivative according to claim 16 wherein

R^{2a} and R^{2b} are each H;

R¹ is-CH₂-A, with A being phenyl or thienyl, optionally substituted by cyano, halogen, methoxy, hydroxy, phenoxy, -NO₂, trifluoromethyl;

Cy is a thienyl, phenyl or biphenyl being substituted by $-SO_2R^3$, $-CO-NR^3R^{3'}$ in which $R^{3'}$ is H and R^3 is (C_7-C_{15}) alkyl, particularly (C_8-C_{15}) alkyl and more particularly a dodecyl group.

Claim 18 (Currently Amended): Substituted The substituted methylene amide derivative of Formula according to claim 16 wherein

R^{2a} and R^{2b} are each H,

 R^1 is selected from the group consisting of phenyl, benzyl, phenethyl, 1-methylbenzyl which may be substituted by (C_1-C_6) alkyl group or a cycloalkyl group;

Cy is a phenyl or a biphenyl group substituted with a moiety selected from the group consisting of -NH-CO-R³, -CO-NH-R³, or an oxadiazole group substituted with R³, wherein R^3 is (C_7-C_{15}) alkyl, particularly (C_8-C_{15}) alkyl and more particularly a dodecyl group.

41

Claims 19-26 (Canceled).

Claim 27 (Currently Amended): A pharmaceutical composition containing comprising at least one substituted methylene amide derivative according to any of claims 1 to 15 claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 28 (Currently Amended): [[A]] <u>The</u> pharmaceutical composition according to claim 27 further comprising at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl urea agents, biguanides (e.g. metformin), thiazolidines, PPARs agonists, c-Jun Kinase or GSK-3 inhibitors.

Claim 29 (Currently Amended): [[A]] The pharmaceutical composition according to claim 28 wherein said supplementary drug is selected from the group consisting of a rapid acting insulin, an intermediate acting insulin, a long acting insulin, a combination of intermediate and rapid acting insulins, Minalrestat, Tolrestat, Sorbinil, Methosorbinil, Zopolrestat, Epalrestat, Zenarestat, Imirestat, Ponalrestat, ONO-2235, GP-1447, CT-112, BAL-ARI 8, AD-5467, ZD5522, M-16209, NZ-314, M-79175, SPR-210, ADN 138, or SNK-860, Miglitol, Acarbose, Glipizide, Glyburide, Chlorpropamide, Tolbutamide, Tolazamide, or Glimepriride.

Claim 30 (Currently Amended): A method of preparing [[a]] the substituted methylene amide derivative according to any of claims 1 to 15 claim 1, comprising: [[the]] coupling step between an amine derivative of formula (III-0) and an ester of formula LG₂-CO-CO-OR⁸, followed by [[a]] hydrolysis[[:]],

wherein Cy, R^1 , R^{2a} , R^{2b} are as above-defined in claim 1, R^8 is a (C_1-C_6) alkyl or cycloalkyl and LG_2 is a leaving group selected from Cl, N-hydroxy succinimide or benzotriazol-1-yl.

Claim 31 (Currently Amended): A method of preparation of [[a]] the substituted methylene amide derivative according to any of claims 1 to 5 and 9 to 15 claim 1, comprising the step of providing the corresponding an ester of formula (I-1) according to the reaction scheme below:

Application No. 10/501,344
Reply to Restriction Requirement of November 16, 2007

wherein X is -CO- or $-SO_2$ -, LG_1 is C1, OH, -Obn, O-Alkyl or O-Alkylaryl and LG_2 is selected from C1, N-hydroxy succinimide or benzotriazol-1-yl, R^8 is a (C_1-C_6) alkyl or cycloalkyl, P is H or a protective group selected from Boc or Fmoc, R^1 , R^{2a} , R^{2b} , R^3 and R^3 are as above defined;

and a subsequent followed by hydrolysis [[step]], thus yielding the methylene amide derivative of formula (I).

Claim 32 (Currently Amended): A method of preparing [[a]] the substituted methylene amide derivative of formula (I) according to any of claims 1 to 5, 9 to 11, 14 and 15 claim 1, comprising: the step of providing the corresponding an ester of formula (I-2) according to the reaction scheme below:

wherein LG_1 is Cl, OH, OBn, O-Alkyl or O-Alkylaryl and LG_2 is selected from Cl, N-hydroxy succinimide or benzotriazol-1-yl, R^8 is a C_1 - C_6 alkyl or cycloalkyl, P is H or a protective group selected from Boc or Fmoc, R^1 , R^{2a} , R^{2b} , R^3 and R^3 are as above defined;

and a subsequent followed by hydrolysis [[step]], thus yielding the methylene amide derivative of formula (I).

Claim 33 (Currently Amended): A method of preparing [[a]] the substituted methylene amide derivative according to any of claims 1 to 11 and 15 claim 1, comprising: the step of providing the corresponding an ester of formula (I-4) according to the reaction scheme below:

Application No. 10/501,344 Reply to Restriction Requirement of November 16, 2007

$$(III-4')$$

$$R^{2a} \longrightarrow R^{3}$$

$$(III-4)$$

$$R^{2a} \longrightarrow R^{3}$$

$$R^{2b} \longrightarrow R^{3}$$

$$R^{3} \longrightarrow R^{3}$$

$$R^{2b} \longrightarrow R^{3}$$

$$R^{2b} \longrightarrow R^{3}$$

$$R^{2b} \longrightarrow R^{3}$$

$$R^{2b} \longrightarrow R^{3}$$

$$R^{3} \longrightarrow R^{3}$$

wherein X is halogen atom selected from the group consisting of Br, I Cl or a leaving group such as $-OSO_2CF_3$, R^8 is an alkyl group, LG_2 is selected from Cl, N-hydroxy succinimide or benzotriazol-1-yl, P is H or a protective group selected from Boc or Fmoc, R^1 , R^{2a} , R^{2b} and R^3 are as above defined;

and a subsequent followed by hydrolysis [[step]], thus yielding the methylene amide derivative of formula (I).

Claim 34 (New): A method for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, selected from the group consisting of diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, appetite regulation, and polycystic ovary syndrome (PCOS), comprising administering to a subject in need thereof an effective amount of substituted methylene amide derivative according to formula (I):

$$\begin{array}{c|cccc}
R^{2a} & R^{1} \\
Cy & N & O \\
R^{2b} & O & OH
\end{array}$$
O OH

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

 R^1 is selected from the group consisting of H, (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, aryl, heteroaryl, (3-8-membered)cycloalkyl or heterocycloalkyl, (C_1-C_{12}) alkyl-aryl or (C_1-C_{12}) alkyl-heteroaryl, (C_2-C_{12}) alkenyl-aryl or -heteroaryl, (C_2-C_{12}) alkynyl-aryl or -heteroaryl;

 R^{2a} and R^{2b} are each independently from each other selected from the group comprising or consisting of H or (C_1-C_{12}) alkyl;

Cy is an aryl, heteroaryl, cycloalkyl or heterocycle.

Claim 35 (New): The method according to claim 34, wherein the metabolic disorders are selected from the group consisting of diabetes type II, obesity or for appetite regulation.

Claim 36 (New): The method according to claim 34, wherein R^{2a}, R^{2b}, R¹ and Cy of the substituted methylene amide derivative are as follows:

R^{2a} and R^{2b} are each H;

R¹ is -CH₂-A, with A being phenyl or thienyl, optionally substituted by cyano, halogen, methoxy, hydroxy, phenoxy, -NO₂, trifluoromethyl;

Cy is a thienyl, phenyl or biphenyl being substituted by $-SO_2R^3$, $-CO-NR^3R^3$ in which R^3 is H and R^3 is (C_7-C_{15}) alkyl, particularly (C_8-C_{15}) alkyl and more particularly a dodecyl group.

Claim 37 (New): The method according to claim 34, wherein R^{2a}, R^{2b}, R¹ and Cy of the substituted methylene amide derivative are as follows:

R^{2a} and R^{2b} are each H;

 R^1 is selected from the group consisting of phenyl, benzyl, phenethyl, 1-methylbenzyl which may be substituted by (C_1-C_6) alkyl group or a cycloalkyl group;

Cy is a phenyl or a biphenyl group substituted with a moiety selected from the group consisting of–NH-CO-R³, -CO-NH-R³, or an oxadiazole group substituted with R³, wherein R^3 is (C_7-C_{15}) alkyl, particularly (C_8-C_{15}) alkyl and more particularly a dodecyl group.

Claim 38 (New): A method for the modulation of the activity of PTPs, comprising administering to a subject in need thereof an effective amount of the substituted methylene amide derivative as defined in claim 34.

Claim 39 (New): The method according to claim 38 wherein the PTP is PTP1B.

Claim 40 (New): The method according to claim 38 wherein said modulation consists in the inhibition of PTP1B.

Claim 41 (New): A method for the treatment or prevention of disorders mediated by PTP1B comprising administering to a subject in need thereof an effective amount of the substituted methylene amide derivative as defined in claim 34.